{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059570","form_type":"8-K","ticker":null,"cik":"0001403708","company_name":"Evoke Pharma Inc","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.266094+00:00","generated_at":"2026-06-02T00:35:56.643099+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evoke Pharma Q1 net product sales up 114% to $1.7M; reiterates $14M 2024 guidance","bullets":["Net product sales of $1.7M vs $0.8M in Q1 2023; net loss of $1.6M ($0.17/share) improved from $2.2M ($0.67/share).","Prescriber count grew 70% QoQ; medication fills increased 10% in Q1 2024 despite February cyberattack on claims processor.","Raised $8.8M gross from public offering and warrant exercises; cash $9.7M expected to fund ops into Q1 2025.","Reaffirmed full-year 2024 net revenue guidance of approximately $14M.","Strengthened distribution partnership with ASPN Pharmacies and plans to present nasal metoclopramide data at DDW 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059570","json":"https://secwatch.observer/filing/0000950170-24-059570.json","markdown":"https://secwatch.observer/filing/0000950170-24-059570.md","text":"https://secwatch.observer/filing/0000950170-24-059570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/0000950170-24-059570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/evok-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:35:56.643099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"738d6d6cea1f4029f7ee57c40a25c41571135130","claim":"Evoke Pharma Inc reported the first quarter ended March 31, 2024 results: revenue approximately $1.7 million, net income approximately $1.6 million, EPS $0.17 per share.","evidence_excerpt":"physicians and the positive experiences shared by patients underscore the growing demand and trust in GIMOTI.” “In the first quarter of 2024, our net revenue of approximately $1.7 million faced marginal impacts from transient challenges, including a cyberattack on the largest U.S. medical claims processor and an increase in co-pay expenses covered by Evoke. The","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017024059570/0000950170-24-059570-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"approximately $1.7 million"},{"label":"Net income","value":"approximately $1.6 million"},{"label":"EPS","value":"$0.17 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}